Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Medicenna Therapeutics Corp. MDNA.TO

Set alert

Price alert · MDNA.TO

All alert types
0.45 CAD +0.02 +4.71%

As of Nov 3, 2:10 PM ET

0.41 Day range 0.445
0.335 52-week range 1.78
YTD
-51.63%
1 year
-70.33%
Open
0.41
Prev close
0.425
Mkt cap
41.07M
Vol
13.80K
Avg vol
49.02K
EPS
-0.22
P/E
0.00
Div yield
0.00%
More statistics
Low
0.41
High
0.445
Forward P/E
-8.00
Beta
1.19
Short ratio
0.55
Inst. own
12.77%
Dividend
0.00
Ex-div date
50-d avg
1.96
200-d avg
2.03
1y target
4.38

2Y chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Dec 6, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (74)
NameDateAgo
SMA: BearishNov 2, 20261 day ago
MACD: Buy SignalOct 28, 20266 days ago
SMA: BullishOct 27, 20261 week ago
MACD: Sell SignalOct 20, 20262 weeks ago
SMA: BearishOct 19, 20262 weeks ago
SMA: BullishOct 6, 20264 weeks ago
MACD: Buy SignalOct 6, 20264 weeks ago
SMA: BearishSep 23, 20261 month ago
SMA: BullishSep 17, 20261 month ago
SMA: BearishSep 15, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
RSI: OverboughtAug 14, 20262 months ago
SMA: BullishAug 10, 20262 months ago
MACD: Buy SignalJul 21, 20263 months ago
MACD: Sell SignalJul 16, 20263 months ago
RSI: OversoldJul 16, 20263 months ago
MACD: Buy SignalJun 4, 20265 months ago
MACD: Sell SignalMay 15, 20265 months ago
MACD: Buy SignalApr 8, 20266 months ago
RSI: OversoldMar 23, 20267 months ago

Newest 20 of 74.

Key statistics

Financials
Market cap
143.81M
Enterprise value
75.73M
Trailing P/E
0.00
Forward P/E
-8.00
PEG ratio
0.00
Price / sales
0.00
Price / book
24.53
EPS (TTM)
-0.38
Beta
1.19
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-30.38K
Total cash
35.63M
Total debt
0
Return on equity
-105.43%
Shares outstanding
78.16M
Short % of float
0.15%
50-day average
1.96
200-day average
2.03

Analyst view

Price target (mean) 4.38 +883.1% upside
Target (low)
3.75
Target (mean)
4.38
Target (high)
5.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy3
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Upgrades / downgrades

MDNA.TO analyst upgrades and downgrades
DateFirmActionFromTo
Dec 6, 2024HC Wainwright & Co.reitBuyBuy
Dec 18, 2020Oppenheimerinit—Outperform
Dec 17, 2020Oppenheimerinit—Outperform
Sep 10, 2020HC Wainwright & Co.init—Buy

About Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Website
medicenna.com

News

All news

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on MDNA.TO — it syncs with the Stock Master app.

Institution ownership

MDNA.TO institution ownership
Holder% heldSharesValueReported
Org Partners LLC 0.16%125,000230.00KSep 29, 2024

Fund ownership

MDNA.TO fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.05%34,14462.82KOct 30, 2023